NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Forecast, Price & News $49.52 +0.15 (+0.30%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$48.60▼$50.1950-Day Range$46.90▼$66.0052-Week Range$37.82▼$68.63Volume351,620 shsAverage Volume603,494 shsMarket Capitalization$3.00 billionP/E RatioN/ADividend YieldN/APrice Target$75.21 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Blueprint Medicines MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside51.9% Upside$75.21 Price TargetShort InterestBearish6.74% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.00Based on 5 Articles This WeekInsider TradingSelling Shares$501,600 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($9.06) to ($7.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector529th out of 968 stocksPharmaceutical Preparations Industry228th out of 439 stocks 4.3 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $75.21, Blueprint Medicines has a forecasted upside of 51.9% from its current price of $49.52.Amount of Analyst CoverageBlueprint Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.74% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Blueprint Medicines has recently increased by 4.60%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPMC. Previous Next 3.3 News and Social Media Coverage News SentimentBlueprint Medicines has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Blueprint Medicines this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows1 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $501,600.00 in company stock.Percentage Held by InsidersOnly 3.88% of the stock of Blueprint Medicines is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($9.06) to ($7.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 5.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Blueprint Medicines (NASDAQ:BPMC) StockBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More BPMC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMC Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comZacks Research Weighs in on Blueprint Medicines Co.'s Q1 2024 Earnings (NASDAQ:BPMC)September 18, 2023 | americanbankingnews.comBlueprint Medicines Co. (NASDAQ:BPMC) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 23, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 13, 2023 | markets.businessinsider.comBerenberg Bank Sticks to Their Buy Rating for Blueprint Medicines (BPMC)September 8, 2023 | finance.yahoo.comDeciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?September 1, 2023 | finance.yahoo.comWhy Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?August 3, 2023 | seekingalpha.comBlueprint Medicines: Rating Downgrade Amid Growth ConcernsAugust 3, 2023 | markets.businessinsider.comWhat 15 Analyst Ratings Have To Say About Blueprint MedicinesSeptember 23, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 3, 2023 | msn.comBlueprint Medicines dips despite Q2 beatAugust 3, 2023 | markets.businessinsider.comBlueprint Medicines (BPMC) Gets a Buy from H.C. WainwrightAugust 2, 2023 | finance.yahoo.comBlueprint Medicines (BPMC) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesAugust 2, 2023 | finance.yahoo.comWhy Shares of Blueprint Medicines Are Falling WednesdayAugust 2, 2023 | seekingalpha.comBlueprint Medicines Corporation 2023 Q2 - Results - Earnings Call PresentationAugust 2, 2023 | finanznachrichten.deBlueprint Medicines Corporation: Blueprint Medicines Reports Second Quarter 2023 ResultsAugust 2, 2023 | finance.yahoo.comBlueprint Medicines Reports Second Quarter 2023 ResultsJuly 31, 2023 | msn.comWells Fargo Upgrades Blueprint Medicines (BPMC)July 19, 2023 | finance.yahoo.comBlueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023July 14, 2023 | msn.comMorgan Stanley Reiterates Blueprint Medicines (BPMC) Equal-Weight RecommendationJuly 5, 2023 | fool.comBlueprint Medicines (NASDAQ: BPMC)June 30, 2023 | reuters.comGenentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner BlueprintJune 30, 2023 | finance.yahoo.comUPDATE 1-Genentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner BlueprintJune 26, 2023 | finance.yahoo.com3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End SoonJune 9, 2023 | finance.yahoo.comBlueprint Medicines (NASDAQ:BPMC) investors are sitting on a loss of 24% if they invested five years agoJune 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC) and Relay Therapeutics (RLAY)June 5, 2023 | msn.comSVB Leerink Downgrades Blueprint Medicines (BPMC)June 5, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Blueprint Medicines (BPMC) and Taro Pharmaceutical (TARO)See More Headlines Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Company Calendar Last Earnings8/02/2023Today9/23/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPMC CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees660Year Founded2011Price Target and Rating Average Stock Price Forecast$75.21 High Stock Price Forecast$114.00 Low Stock Price Forecast$38.00 Forecasted Upside/Downside+51.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($9.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-557,520,000.00 Net Margins-245.62% Pretax Margin-244.46% Return on Equity-117.88% Return on Assets-43.17% Debt Debt-to-Equity Ratio0.39 Current Ratio4.80 Quick Ratio4.70 Sales & Book Value Annual Sales$204.04 million Price / Sales14.72 Cash FlowN/A Price / Cash FlowN/A Book Value$8.60 per share Price / Book5.76Miscellaneous Outstanding Shares60,670,000Free Float58,311,000Market Cap$3.00 billion OptionableOptionable Beta0.74 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Kathryn Haviland (Age 47)Pres, CEO & Director Comp: $1.17MMr. Alexis A. Borisy A.M. (Age 51)Co-Founder & Director Comp: $50kMr. Michael Landsittel (Age 51)Chief Financial Officer Comp: $785.36kMs. Christina Rossi (Age 46)Chief Operating Officer Comp: $875.22kMs. Tracey L. McCain Esq. (Age 55)Exec. VP, Chief Legal & Compliance Officer and Sec. Comp: $764.9kDr. Fouad Namouni M.D. (Age 54)Pres of R&D Comp: $916.4kMs. Ariel Hurley (Age 49)Sr. VP, Fin. & Principal Accounting Officer Dr. Christopher K. Murray Ph.D. (Age 59)Sr. VP of Technical Operations and Chief Technical Operations & Quality Officer Dr. Percy H. Carter M.B.A. (Age 52)Ph.D., Chief Scientific Officer Jenna CohenSr. Director & Head of Investor RelationsMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLCytokineticsNASDAQ:CYTKIndiviorNASDAQ:INDVArrowhead PharmaceuticalsNASDAQ:ARWRAkero TherapeuticsNASDAQ:AKROView All CompetitorsInsiders & InstitutionsJeffrey W AlbersSold 10,000 sharesTotal: $501,600.00 ($50.16/share)Wolverine Trading LLCSold 6,600 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 25,900 shares on 8/22/2023Ownership: 0.043%California State Teachers Retirement SystemSold 1,781 shares on 8/21/2023Ownership: 0.120%Teachers Retirement System of The State of KentuckySold 4,714 shares on 8/21/2023Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions BPMC Stock - Frequently Asked Questions Should I buy or sell Blueprint Medicines stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 2 sell ratings, 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BPMC shares. View BPMC analyst ratings or view top-rated stocks. What is Blueprint Medicines' stock price forecast for 2023? 12 brokerages have issued twelve-month target prices for Blueprint Medicines' shares. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they anticipate the company's stock price to reach $75.21 in the next year. This suggests a possible upside of 51.9% from the stock's current price. View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts. How have BPMC shares performed in 2023? Blueprint Medicines' stock was trading at $43.81 on January 1st, 2023. Since then, BPMC stock has increased by 13.0% and is now trading at $49.52. View the best growth stocks for 2023 here. When is Blueprint Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our BPMC earnings forecast. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) posted its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($2.19) earnings per share for the quarter, beating analysts' consensus estimates of ($2.58) by $0.39. The biotechnology company had revenue of $57.60 million for the quarter, compared to the consensus estimate of $45.60 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 117.88% and a negative net margin of 245.62%. The firm's quarterly revenue was up 57.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.68) EPS. What ETFs hold Blueprint Medicines' stock? ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Fidelity Disruptive Medicine ETF (FMED), Harbor Corporate Culture Small Cap ETF (HAPS), BlackRock Future Health ETF (BMED) and Principal Healthcare Innovators ETF (BTEC). What is Kate Haviland's approval rating as Blueprint Medicines' CEO? 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR). When did Blueprint Medicines IPO? (BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Blueprint Medicines' stock symbol? Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC." Who are Blueprint Medicines' major shareholders? Blueprint Medicines' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.77%), State Street Corp (4.13%), Rock Springs Capital Management LP (3.60%), Alliancebernstein L.P. (2.66%), JPMorgan Chase & Co. (2.65%) and William Blair Investment Management LLC (2.43%). Insiders that own company stock include Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Percy H Carter and Tracey L Mccain. View institutional ownership trends. How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Blueprint Medicines' stock price today? One share of BPMC stock can currently be purchased for approximately $49.52. How much money does Blueprint Medicines make? Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.00 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.22) on an earnings per share basis. How many employees does Blueprint Medicines have? The company employs 660 workers across the globe. How can I contact Blueprint Medicines? Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com. This page (NASDAQ:BPMC) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.